GlassScriptPhysician profile
Josna Haritha
NPI 1922445097
$10,373.62
in general payments reported to CMS, 2019-2025
33 companies · $2,918 in 2025
The $2,918 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $864 · 2021: $1,013 · 2022: $1,368 · 2023: $1,321 · 2024: $2,165 · 2025: $2,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,160 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,160.45 |
| Education | $243.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,393.77 | 2019-2025 | |
| Amgen INC. | $1,776.92 | 2019-2025 | Tavneos, Enbrel, Evenity |
| Janssen Biotech, INC. | $696.62 | 2020-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $591.82 | 2019-2025 | |
| Genzyme Corporation | $529.72 | 2019-2025 | |
| Pfizer INC. | $523.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.60 | 2020-2025 | Ofev, Cyltezo, Jascayd |
| Glaxosmithkline, LLC. | $411.99 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $410.54 | 2019-2025 | Taltz |
| Ucb, INC. | $401.87 | 2022-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $382.62 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $323.81 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $230.74 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $186.30 | 2022-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $135.32 | 2024-2025 | Strensiq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $134.13 | 2021-2025 | Tymlos |
| Sandoz INC. | $110.61 | 2023-2024 | Hyrimoz |
| Sobi, INC | $101.43 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $90.50 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $87.03 | 2023-2024 | Purified Cortrophin Gel |
| Hikma Pharmaceuticals USA | $71.74 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $59.45 | 2022-2023 | Acthar |
| Kiniksa Pharmaceuticals International, Plc | $56.78 | 2024 | Arcalyst |
| Genentech USA, INC. | $47.01 | 2024-2025 | Actemra |
| Idorsia Pharmaceuticals US INC | $37.01 | 2023-2024 | Quviviq |
| Hospira, INC. | $26.76 | 2025 | |
| Janssen Pharmaceuticals, INC | $25.68 | 2024 | Opsumit |
| Avanos Medical | $23.69 | 2023 | Genvisc 850 Sodium Hyaluronate |
| Mallinckrodt Enterprises LLC | $18.61 | 2019 | |
| Fidia Pharma USA INC. | $17.58 | 2020 | |
| Biocon Biologics INC | $17.23 | 2023 | Hulio |
| Organon LLC | $14.70 | 2024 | |
| Shorla Oncology INC. | $14.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josna Haritha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.